News

Net Loss of Indoco Remedies reported to Rs 21.64 crore in the quarter ended March 2026 as against net loss of Rs 40.39 crore during the previous quarter ended March 2025. Sales rose 18.76% to Rs 455.90 crore in the quarter ended March 2026 as against Rs 383.89 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 95.15 crore in the year ended March 2026 as against net loss of Rs 73.74 crore during the previous year ended March 2025. Sales rose 9.24% to Rs 1792.94 crore in the year ended March 2026 as against Rs 1641.29 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales455.90383.89 19 1792.941641.29 9 OPM %10.90-0.20 -7.916.05 - PBDT3.75-16.74 LP 22.8838.48 -41 PBT-28.74-45.52 37 -103.57-75.36 -37 NP-21.64-40.39 46 -95.15-73.74 -29 Powered by Capital Market - Live News

Indoco Remedies announced that the Board of Directors of the Company at its meeting held on 07 May 2026, has recommended a Final Dividend of Rs.0.20 per share (i.e.10%), subject to the approval of the shareholders.

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Net Loss of Indoco Remedies reported to Rs 29.79 crore in the quarter ended December 2025 as against net loss of Rs 26.39 crore during the previous quarter ended December 2024. Sales rose 7.92% to Rs 434.34 crore in the quarter ended December 2025 as against Rs 402.45 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales434.34402.45 8 OPM %7.252.99 - PBDT6.85-3.23 LP PBT-25.16-31.95 21 NP-29.79-26.39 -13 Powered by Capital Market - Live News

Indoco Remedies has allotted 55,700 equity shares under ESOP on 03 February 2026. Consequent to this allotment, the paid up equity share capital has increased to Rs. 18,46,07,210 (consisting of 9,23,03,605 equity shares of face value of Rs. 2 each). Powered by Capital Market - Live News